Modeling of high-affinity binding of the novel atrial anti-arrhythmic agent, vernakalant, to Kv1.5 channels

Journal of Molecular Graphics and Modelling

Volumn 28, Issue 3, 2009, Pages 226-235

  Eldstrom, Jodene ^a   Fedida, David ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Atrial fibrillation; AutoDock; Kv1.5; Vernakalant

Indexed keywords

AFFINITY BINDING; ATRIAL FIBRILLATION; AUTODOCK; BINDING CONFORMATIONS; CHANNEL INTERACTIONS; CHANNEL MODEL; CHANNEL PORE; CHANNEL STRUCTURES; DOCKING SIMULATIONS; FREE ENERGY OF BINDING; INHIBITORY CONCENTRATION; KV1.5; PATCH-CLAMP STUDIES; POINT MUTATIONS; POTENTIAL BINDING; SINUS RHYTHM; VERNAKALANT;

DOCKING; DRUG INTERACTIONS;

BINDING ENERGY;

POTASSIUM CHANNEL KV1.5; VERNAKALANT;

ARTICLE; BINDING AFFINITY; COMPUTER PROGRAM; DRUG BINDING; DRUG CONFORMATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; MOLECULAR DOCKING; MOLECULAR MODEL; PATCH CLAMP; POINT MUTATION; PRIORITY JOURNAL; PROTEIN STRUCTURE; SIMULATION;

AMINO ACID SEQUENCE; ANISOLES; ANTI-ARRHYTHMIA AGENTS; BINDING SITES; HUMANS; KV1.5 POTASSIUM CHANNEL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR DYNAMICS SIMULATION; MOLECULAR SEQUENCE DATA; POTASSIUM CHANNEL BLOCKERS; PROTEIN BINDING; PYRROLIDINES; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 70349527868     PISSN: 10933263     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmgm.2009.07.005     Document Type: Article

References (28)

1. Roy D., Rowe B.H., Stiell I.G., Coutu B., Ip J.H., Phaneuf D., Lee J., Vidaillet H., Dickinson G., Grant S., Ezrin A.M., and Beatch G.N. A randomized, controlled trial of RSD1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J. Am. Coll. Cardiol. 44 (2004) 2355-2361
2. Roy D., Pratt C.M., Torp-Pedersen C., Wyse D.G., Toft E., Juul-Moller S., Nielsen T., Rasmussen S.L., Stiell I.G., Coutu B., Ip J.H., Pritchett E.L., and Camm A.J. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial. Circulation 117 (2008) 1518-1525
3. Savelieva I., and Camm J. Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. Europace 10 (2008) 647-665
4. Eldstrom J., Wang Z., Xu H., Pourrier M., Ezrin A., Gibson K., and Fedida D. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol. Pharmacol. 72 (2007) 1522-1534
5. Fedida D., Orth P.M.R., Chen J.Y.C., Lin S., Plouvier B., Jung G., Ezrin A., and Beatch G.N. The mechanism of atrial antiarrhythmic action of RSD1235. J. Cardiovasc. Electrophysiol. 16 (2005) 1227-1238
6. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin. Investig. Drugs 16 (2007) 519-532
7. + channel current. Circ. Res. 73 (1993) 210-216
8. + current in cultured adult human atrial myocytes. Circ. Res. 80 (1997) 572-579
9. Caballero R., Moreno I., Gonzalez T., Valenzuela C., Tamargo J., and Delpon E. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc. Res. 56 (2002) 104-117
10. + channels. J. Biol. Chem. 279 (2004) 394-400
11. Decher N., Kumar P., Gonzalez T., Pirard B., and Sanguinetti M.C. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol. Pharmacol. 70 (2006) 1204-1211
12. Herrera D., Mamarbachi A., Simoes M., Parent L., Sauve R., Wang Z., and Nattel S. A single residue in the S6 transmembrane domain governs the differential flecainide sensitivity of voltage-gated potassium channels. Mol. Pharmacol. 68 (2005) 305-316
13. + channel-role of S6 in antiarrhythmic drug binding. Circ. Res. 78 (1996) 1105-1114
14. Morris G.M., Goodsell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., and Olson A.J. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19 (1998) 1639-1662
15. Huey R., Morris G.M., Olson A.J., and Goodsell D.S. A semiempirical free energy force field with charge-based desolvation. J. Comput. Chem. 28 (2007) 1145-1152
16. + channel. Science 309 (2005) 897-903
17. Trott O., and Olson A.J. AuoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. June (2009) (Epub ahead of print)
18. Hetenyi C., and van der S.D. Efficient docking of peptides to proteins without prior knowledge of the binding site. Protein Sci. 11 (2002) 1729-1737
19. + channel in a lipid membrane-like environment. Nature 450 (2007) 376-382
20. Pirard B., Brendel J., and Peukert S. The discovery of Kv1.5 blockers as a case study for the application of virtual screening approaches. J. Chem. Inf. Model. 45 (2005) 477-485
21. Liu H.L., Chen C.W., and Lin J.C. Homology models of the tetramerization domain of six eukaryotic voltage-gated potassium channels Kv1.1-Kv1.6. J. Biomol. Struct. Dyn. 22 (2005) 387-398
22. Luzhkov V.B., Nilsson J., Arhem P., and Aqvist J. Computational modelling of the open-state Kv 1.5 ion channel block by bupivacaine. Biochim. Biophys. Acta 1652 (2003) 35-51
23. Yang Q., Du L., Wang X., Li M., and You Q. Modeling the binding modes of Kv1.5 potassium channel and blockers. J. Mol. Graph. Model. 27 (2008) 178-187
24. Strutz-Seebohm N., Gutcher I., Decher N., Steinmeyer K., Lang F., and Seebohm G. Comparison of potent Kv1.5 potassium channel inhibitors reveals the molecular basis for blocking kinetics and binding mode. Cell. Physiol. Biochem. 20 (2007) 791-800
25. Ander M., Luzhkov V.B., and Aqvist J. Ligand binding to the voltage-gated Kv1.5 potassium channel in the open state-docking and computer simulations of a homology model. Biophys. J. 94 (2008) 820-831
26. Bruhova I., and Zhorov B.S. Monte Carlo-energy minimization of correolide in the Kv1.3 channel: possible role of potassium ion in ligand-receptor interactions. BMC Struct. Biol. 7 (2007) 5
27. Lerche C., Bruhova I., Lerche H., Steinmeyer K., Wei A.D., Strutz-Seebohm N., Lang F., Busch A.E., Zhorov B.S., and Seebohm G. Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter. Mol. Pharmacol. 71 (2007) 1503-1511
28. Vakser I.A., and Aflalo C. Hydrophobic docking: a proposed enhancement to molecular recognition techniques. Proteins 20 (1994) 320-329